MedPath

Esokalli Testosterone Booster Oral Dissolving Film

Approved
Approval ID

3d710111-debf-ff99-e063-6294a90a3186

Product Type

HUMAN OTC DRUG LABEL

Effective Date

Sep 1, 2025

Manufacturers
FDA

Guangzhou Yixin Cross-border E-commerce Co., Ltd.

DUNS: 455800881

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Esokalli Testosterone Booster Oral Dissolving Film

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code84778-083
Application Number505G(a)(3)
Product Classification
M
Marketing Category
C200263
G
Generic Name
Esokalli Testosterone Booster Oral Dissolving Film
Product Specifications
Route of AdministrationTOPICAL
Effective DateSeptember 1, 2025
FDA Product Classification

INGREDIENTS (5)

VARDENAFILActive
Quantity: 10 mg in 100 mg
Code: UCE6F4125H
Classification: ACTIB
HYPROMELLOSESInactive
Code: 3NXW29V3WO
Classification: IACT
TADALAFILActive
Quantity: 30 mg in 100 mg
Code: 742SXX0ICT
Classification: ACTIB
SUCRALOSEInactive
Code: 96K6UQ3ZD4
Classification: IACT
SUCROSEInactive
Code: C151H8M554
Classification: IACT

Drug Labeling Information

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOINC: 51945-4Updated: 8/24/2025

PRINCIPAL DISPLAY PANEL

1234

INDICATIONS & USAGE SECTION

LOINC: 34067-9Updated: 8/24/2025

Uses

For the treatment of erectile dysfunction (ED)

COMPONENTS

LOINC: 60559-2Updated: 9/2/2025

Active ingredients (in each film)

Tadalafil 30 mg – Erectile dysfunction treatment
Vardenafil 10 mg – Erectile dysfunction treatment

OTC - PURPOSE SECTION

LOINC: 55105-1Updated: 8/24/2025

Purpose

Phosphodiesterase type 5 (PDE5) inhibitors

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

LOINC: 50565-1Updated: 8/24/2025

Contraindications

Not for use in pregnant or breastfeeding women
Not for use in children under 18 years

WARNINGS SECTION

LOINC: 34071-1Updated: 8/24/2025

Warnings

For adult men only.

DOSAGE & ADMINISTRATION SECTION

LOINC: 34068-7Updated: 8/24/2025

Dosage and administration

• Take 1 oral film as a single dose.
• Administer orally by placing on the tongue until dissolved.
• Administer approximately 0.5 to 4 hours prior to anticipated sexual activity.
• Do not exceed 1 dose in 24 hours.

OTC - DO NOT USE SECTION

LOINC: 50570-1Updated: 8/24/2025

Do not use if you:

take nitrate medicines (such as nitroglycerin)
have severe heart disease or very low blood pressure
are allergic to tadalafil, vardenafil, or any ingredient in this product
have galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption

OTC - WHEN USING SECTION

LOINC: 50567-7Updated: 8/24/2025

When using this product you may experience:

headache, flushing, indigestion, nasal congestion, dizziness, muscle pain, back pain, nausea, rash, or visual disturbances

OTC - STOP USE SECTION

LOINC: 50566-9Updated: 8/24/2025

Stop use and ask a doctor if:

you experience chest pain, fainting, sudden vision or hearing loss
an erection lasts longer than 4 hours (priapism). This is a medical emergency.

INACTIVE INGREDIENT SECTION

LOINC: 51727-6Updated: 8/24/2025

Inactive ingredients

Film-forming polymers, stabilizers, sweeteners, flavoring agents.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.